RecruitingPhase 1NCT06362980

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Studying NLRP3-associated autoinflammatory disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Center, China
Principal Investigator
Puyuan Xing, Doctorate
Department of Medical Oncology, National Cancer Center, China
Intervention
BPI-1178(drug)
Enrollment
20 target
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06362980 on ClinicalTrials.gov

Other trials for NLRP3-associated autoinflammatory disease

Additional recruiting or active studies for the same condition.

See all trials for NLRP3-associated autoinflammatory disease

← Back to all trials